Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Brandywine Global Investment Management LLC

Brandywine Global Investment Management LLC lifted its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 7.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,958,302 shares of the biopharmaceutical company's stock after buying an additional 142,176 shares during the quarter. Brandywine Global Investment Management LLC owned 0.33% of Royalty Pharma worth $49,956,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Brooklyn Investment Group lifted its position in shares of Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 876 shares in the last quarter. Allworth Financial LP increased its stake in Royalty Pharma by 417.6% during the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 877 shares during the period. Riverview Trust Co lifted its holdings in Royalty Pharma by 3,953.3% in the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 1,186 shares in the last quarter. Fifth Third Bancorp boosted its position in Royalty Pharma by 187.1% in the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 997 shares during the last quarter. Finally, Blue Trust Inc. grew its stake in shares of Royalty Pharma by 31.3% during the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 376 shares in the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Royalty Pharma Stock Up 0.4 %

Royalty Pharma stock traded up $0.11 during midday trading on Wednesday, hitting $31.28. The stock had a trading volume of 4,635,069 shares, compared to its average volume of 3,139,831. The business has a fifty day moving average price of $32.47 and a 200 day moving average price of $28.91. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $34.20. The stock has a market cap of $18.03 billion, a P/E ratio of 21.57, a P/E/G ratio of 2.31 and a beta of 0.47. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Research analysts predict that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 10th. Shareholders of record on Friday, February 21st were issued a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.81%. This is a boost from Royalty Pharma's previous quarterly dividend of $0.21. The ex-dividend date was Friday, February 21st. Royalty Pharma's dividend payout ratio is 60.69%.

Wall Street Analyst Weigh In

Several research firms recently commented on RPRX. TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a research note on Tuesday, December 24th. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Royalty Pharma has an average rating of "Buy" and a consensus price target of $41.60.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.